Research programme: MIF inhibitors - Novartis

Drug Profile

Research programme: MIF inhibitors - Novartis

Alternative Names: AVP-13748; AVP-28225

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator Avanir Pharmaceuticals
  • Developer Novartis
  • Class Small molecules
  • Mechanism of Action Macrophage migration inhibitory factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 13 Jul 2010 Preclinical development is ongoing in USA
  • 30 Mar 2007 Preclinical development is ongoing
  • 04 Oct 2005 Avanir and Novartis have entered into a global research, development and commercialisation agreement to develop molecules targeting MIF for inflammatory disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top